1-3 of 3
Carsten Schultz-Fademrecht
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CDK9 Inhibition with LDC526 Is an Effective Treatment for T-Cell Prolymphocytic Leukemia (T-PLL) in Vitro

Patricia Johansson, MD, Peter Habenberger, PhD, Ludger Klein-Hitpass, PhD, Ulrich Duehrsen, MD, Ralf Küppers, PhD, Carsten Schultz-Fademrecht, PhD, Axel Choidas, PhD, Jan Dürig, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1262.
https://doi.org/10.1182/blood.V130.Suppl_1.1262.1262
Published: 2017
Journal Articles

Preclinical Testing Of a Novel Axl-Kinase Inhibitor In Chronic Lymphocytic Leukemia

Maria Göbel, Michael Möllmann, André Görgens, PhD, Ulrich Dührsen, MD, Joachim Rudolf Göthert, MD, Bernd Giebel, Carsten Schultz-Fademrecht, Anke Unger, Bert Klebl, Axel Choidas, Jan Dürig, MD
Journal: Blood
Blood (2013) 122 (21): 2879.
https://doi.org/10.1182/blood.V122.21.2879.2879
Published: 2013
Journal Articles

Potent Anti-Leukemic Activity of a Novel Cdk9 Inhibitor in Preclinical CLL Mouse Models

Joachim Rudolf Göthert, MD, Roze Imsak, Michael Möllmann, Stefanie Weber, Mandy Necke, Ulrich Dührsen, MD, Jan Eickhoff, Matthias Baumann, Anke Unger, Carsten Schultz-Fademrecht, Jan Dürig, MD
Journal: Blood
Blood (2011) 118 (21): 1789.
https://doi.org/10.1182/blood.V118.21.1789.1789
Published: 2011